Abstract: 【Abstract】The incidence of chronic kidney disease (CKD) is high. CKD is insidious at the early stage and may evolve gradually to end-stage renal disease (ESRD), at which patients have to rely on dialysis or kidney transplantation with a heavy financial burden. CKD has become a social and public problem that seriously threatens public health. CKD patients at late stage are often accompanied by various degrees of calcium and phosphorus metabolic disorders, anemia, secondary hyperparathyroidism, cardiovascular disease and others. Many studies have found that fibroblast growth factor 23 (FGF23) is involved in the regulation of calcium and phosphorus metabolism as well as in erythropoiesis in CKD patients. Further studies on FGF23 may bring a
breakthrough in the clinical treatment of anemia in CKD patients.

Key words: Chronic kidney disease, Fibroblast growth factor 23, Anemia, Hypoxia-inducible factorr